| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5825918 | Current Opinion in Pharmacology | 2016 | 8 Pages |
Abstract
HDL cholesterol raising and triglyceride lowering therapies have not yet shown unequivocal benefits for cardiovascular risk reduction. New therapies in these areas are in development, and their future promise remains to be demonstrated.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Sarah Bou Malham, Anne Carol Goldberg,